News and Trends 23 Jul 2020 Pharma Giant GSK and mRNA Biotech CureVac Ink €1B Deal GlaxoSmithKline (GSK) has struck a deal worth up to €1B with the German biotechnology company CureVac to co-develop messenger RNA drugs for infectious diseases. Under the terms of the deal, GSK will fund the development and manufacturing of up to five mRNA-based vaccines and antibody drugs targeting undisclosed infectious diseases. CureVac’s current rabies and Covid-19 […] July 23, 2020 - 3 minutesmins - By David Wilson Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2020 Sanofi Enlists Cell Therapy Firm Kiadis in €875M Immuno-Oncology Deal The Dutch biotech Kiadis Pharma has licensed an off-the-shelf cell therapy program to the pharma giant Sanofi for up to €857.5M in a deal aiming to develop a combination immunotherapy for the blood cancer multiple myeloma. The preclinical-stage cell therapy that Kiadis licensed is based on genetically modifying donor immune cells called natural killer cells, […] July 13, 2020 - 3 minutesmins - By David Wilson Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2020 Forbion Raises €185M to Fuel Late-Stage European Biotechs The Dutch life sciences venture capital firm Forbion has bagged €185M in the first closing of a fund aimed at investing in late-stage European biotech companies, which often struggle to raise capital. The main mission of Forbion’s fund — named the Growth Opportunities Fund — is to invest in European life sciences companies raising their […] July 13, 2020 - 3 minutesmins - By David Wilson Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2020 Swiss Regenerative Medicine Biotech Closes €19M Series B The regenerative medicine startup Cutiss has raised €18.8M (CHF 20M) to commercialize its personalized skin graft treatment for burn patients in Switzerland and the European Union around 2022. This is the final closing of a Series B round announced earlier this month. The lead investor in the oversubscribed round was the Swiss firm Gisev Family […] July 1, 2020 - 3 minutesmins - By David Wilson Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2020 Swedish Biotech’s Psoriasis Drug Beats Placebo in Phase II A new class of drug developed by the Swedish biotech company Affibody has proved better at treating symptoms of psoriasis than a placebo in a phase II trial, leading the company to develop the candidate for other conditions such as uveitis and psoriatic arthritis. The phase II study enlisted 108 patients with psoriasis, a chronic […] June 22, 2020 - 3 minutesmins - By David Wilson Share WhatsApp Twitter Linkedin Email